XOMA Royalty Corp (XOMA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $40.17
- As of
Kresmion compiles this page from XOMA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
XOMA Royalty Corp (XOMA): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-14.
See the full XOMA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XOMA on one page. Preview it with sample data, then open it live with a free account.
Preview the XOMA dossierActive signals for XOMA
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +407% to XOMA (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 85% of XOMA (2026Q2)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 295.5% - EPS $0.44 vs $-0.2251 estimate
- lowEARNINGS_BEAT
Q3-2025: EPS $0.70 vs $-0.0408 estimate, +0.74 on a near-zero consensus
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 264.5% - EPS $0.26 vs $-0.1581 estimate
FREE, NO ACCOUNT
Every signal on XOMA, as it fires
You are seeing 5 of 6 signals recorded on XOMA since 2026-05-30.
The five above landed across 2 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XOMA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 98419J206 · 2026Q2 | $8.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 98419J206 · 2026Q2 | $1.6M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 98419J206 · 2026Q2 | $1.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XOMA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
XOMA against its peers
XOMA's operating margin of 110.0% ranks in the 95th percentile of 10 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | XOMA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 10.3M USD | 49.8M USD | 29 | 11 |
| Operating margin | 110.0% | -142.7% | 95 | 10 |
| Net margin | 306.4% | -132.8% | 95 | 10 |
| Return on equity | 37.8% | -38.4% | 93 | 20 |
| 1 year | n/a | -2.8% | n/a | 19 |
Peers (20): MDXG, CADL, FDMT, SLDB, VSTM, ACHV, GYRE, PHAR, ZVRA, IMMX, PRME, GERN, DSGN, OLMA, WVE, ANNX, AURA, AVTX, LXRX, CLYM. Left out: IVA (period gap), HELP (period gap), APMD (no annual filing), OBX (no annual filing), BLSM (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (XOMA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XOMA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XOMA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.